Harbor Advisors’s Novo Nordisk NVO Stock Holding History

Harbor Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,800	Closed	-$241K	–	198
2024 Q4	$241K	Buy	+2,800	New	+$303K	0.04%	167

Other funds holding NVO

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Harbor Advisors's NVO Position: Q1 2025 in Review

Harbor Advisors sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 2,800 shares — an estimated $241K sold.

Harbor Advisors first reported a position in NVO in Q4 2024 and held it in 1 quarter. The position peaked at $241K in Q4 2024. 1,530 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

Harbor Advisors reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
Harbor Advisors sold 2,800 Novo Nordisk shares in Q1 2025, an estimated $241K.
Harbor Advisors first reported a position in Novo Nordisk in Q4 2024 and held it in 1 quarter.
Harbor Advisors's Novo Nordisk position peaked at $241K in Q4 2024.
1,530 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Harbor Advisors's 13F filing for Q1 2025, filed 15 May 2025.